JP2013522376A - 変性疾患を治療するための組成物および方法 - Google Patents

変性疾患を治療するための組成物および方法 Download PDF

Info

Publication number
JP2013522376A
JP2013522376A JP2013501494A JP2013501494A JP2013522376A JP 2013522376 A JP2013522376 A JP 2013522376A JP 2013501494 A JP2013501494 A JP 2013501494A JP 2013501494 A JP2013501494 A JP 2013501494A JP 2013522376 A JP2013522376 A JP 2013522376A
Authority
JP
Japan
Prior art keywords
compound
formula
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013501494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522376A5 (enExample
Inventor
クレイグ キャノ ビーソン，
ベイアブル ローラー，
ネイサン アール． ペロン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical University of South Carolina
Original Assignee
Medical University of South Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical University of South Carolina filed Critical Medical University of South Carolina
Publication of JP2013522376A publication Critical patent/JP2013522376A/ja
Publication of JP2013522376A5 publication Critical patent/JP2013522376A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013501494A 2010-03-24 2011-03-24 変性疾患を治療するための組成物および方法 Pending JP2013522376A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31718510P 2010-03-24 2010-03-24
US61/317,185 2010-03-24
PCT/US2011/029846 WO2011119869A1 (en) 2010-03-24 2011-03-24 Compositions and methods for the treatment of degenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015189524A Division JP2015232051A (ja) 2010-03-24 2015-09-28 変性疾患を治療するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2013522376A true JP2013522376A (ja) 2013-06-13
JP2013522376A5 JP2013522376A5 (enExample) 2014-05-08

Family

ID=43927957

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013501494A Pending JP2013522376A (ja) 2010-03-24 2011-03-24 変性疾患を治療するための組成物および方法
JP2015189524A Pending JP2015232051A (ja) 2010-03-24 2015-09-28 変性疾患を治療するための組成物および方法
JP2016156126A Pending JP2016188257A (ja) 2010-03-24 2016-08-09 変性疾患を治療するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015189524A Pending JP2015232051A (ja) 2010-03-24 2015-09-28 変性疾患を治療するための組成物および方法
JP2016156126A Pending JP2016188257A (ja) 2010-03-24 2016-08-09 変性疾患を治療するための組成物および方法

Country Status (6)

Country Link
US (2) US20130137728A1 (enExample)
EP (1) EP2550260A1 (enExample)
JP (3) JP2013522376A (enExample)
AU (1) AU2011232347B2 (enExample)
CA (1) CA2794018C (enExample)
WO (1) WO2011119869A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020019786A (ja) * 2015-04-30 2020-02-06 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント オキシンドール化合物およびその医薬組成物

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
WO2014059008A1 (en) 2012-10-09 2014-04-17 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
CN104703585A (zh) 2012-10-09 2015-06-10 宝洁公司 鉴定协同化妆品组合的方法
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9079853B2 (en) 2013-02-07 2015-07-14 Musc Foundation For Research Development Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
US20140275178A1 (en) * 2013-03-13 2014-09-18 Musc Foundation For Research Development Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders
US8921401B2 (en) 2013-02-07 2014-12-30 Musc Foundation For Research Development Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
DK2956056T3 (da) 2013-03-14 2019-09-16 Univ Laval Elektroretinografisystem (erg) til vurdering af psykiatriske lidelser
CA2957785C (en) 2014-08-11 2023-01-03 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
CA2970819A1 (en) 2014-12-31 2016-07-07 Angion Biomedica Corp. Methods and agents for treating disease
CN104803946A (zh) * 2015-03-03 2015-07-29 佛山市赛维斯医药科技有限公司 含腈基噻唑和环戊二烯结构的ptp1b抑制剂及其用途
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
TWI666023B (zh) * 2016-09-26 2019-07-21 台灣粒線體應用技術股份有限公司 餘甘子萃取物用於製備保護視網膜中粒線體的醫藥組合物的用途
US10967019B2 (en) 2015-11-30 2021-04-06 Taiwan Mitochondrion Applied Technology Co., Ltd. Method for protecting mitochondria in retina cell
EP3426653B1 (en) * 2016-03-11 2021-12-15 AC Immune SA Bicyclic compounds for diagnosis and therapy
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
MX2021012250A (es) 2019-04-11 2022-01-18 Angion Biomedica Corp Formas solidas de (e)-3-[2-(2-tienil)vinil]-1h-pirazol.
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
BR112022019113A2 (pt) 2020-03-26 2022-12-06 Diamentis Inc Sistemas e métodos para processar dados de sinal da retina e identificar condições
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
KR20240138099A (ko) * 2022-01-26 2024-09-20 쑤저우 젠하우스 바이오 컴퍼니 리미티드 Mtap 결실 암을 치료하기 위한 메티오닌 아데노실트랜스퍼라제 2a 억제제
WO2023150878A1 (en) 2022-02-09 2023-08-17 Diamentis Inc. Systems and methods for retinal stimulation and/or collecting retinal signal data
EP4582423A1 (en) * 2022-10-13 2025-07-09 Hanmi Pharm. Co., Ltd. Novel tricyclic derivative compound and uses thereof
AR131380A1 (es) 2022-12-16 2025-03-12 Astrazeneca Ab Purinas 2,6,9-trisustituidas

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852293A (en) * 1972-06-21 1974-12-03 Uniroyal Inc 4-phenyl-2-(3-pyridyl)-thiazole carboxamides
US4260765A (en) * 1971-05-05 1981-04-07 Uniroyal, Inc. 2-(3-Pyridyl)-5-thiazolecarboxamides
JPS57183768A (en) * 1981-05-06 1982-11-12 Kanto Ishi Pharma Co Ltd 4-methyl-5-(o-carboxyphenyl)carbamoylthiazole derivative and its preparation
US4788207A (en) * 1988-02-29 1988-11-29 Fmc Corporation Photoactivated miticidal and insecticidal ethynylthiazoles
JP2005531596A (ja) * 2002-05-31 2005-10-20 プロテオテック・インコーポレイテッド アミロイド疾患およびシヌクレイノパチー（例えばアルツハイマー病、タイプ２型糖尿病、およびパーキンソン病）を処置するための化合物、組成物、および方法
WO2006094237A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators
WO2008090382A1 (en) * 2007-01-25 2008-07-31 The University Of Sheffield Thiazole and oxazole derivatives for use in the treatment of prion diseases, cancer and conditions of the central nervous system as well as in the regulation of stem cells
JP2008536941A (ja) * 2005-04-20 2008-09-11 ゼノン・ファーマシューティカルズ・インコーポレイテッド オキシインドール化合物および治療剤としてのその使用
WO2008156869A2 (en) * 2007-06-20 2008-12-24 Sirtris Pharmaceuticals, Inc. Sirtuin modulating thiazolopyridine compounds
WO2009055828A1 (en) * 2007-10-25 2009-04-30 Medivation Technologies, Inc. New tetracyclic compounds
WO2009064388A2 (en) * 2007-11-09 2009-05-22 Liu Jun O Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19845402B4 (de) * 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
EP1402900A1 (en) * 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
US7259175B2 (en) * 2002-02-25 2007-08-21 Eli Lilly And Company Peroxisome proliferator activated receptor modulators

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260765A (en) * 1971-05-05 1981-04-07 Uniroyal, Inc. 2-(3-Pyridyl)-5-thiazolecarboxamides
US3852293A (en) * 1972-06-21 1974-12-03 Uniroyal Inc 4-phenyl-2-(3-pyridyl)-thiazole carboxamides
JPS57183768A (en) * 1981-05-06 1982-11-12 Kanto Ishi Pharma Co Ltd 4-methyl-5-(o-carboxyphenyl)carbamoylthiazole derivative and its preparation
US4788207A (en) * 1988-02-29 1988-11-29 Fmc Corporation Photoactivated miticidal and insecticidal ethynylthiazoles
JP2005531596A (ja) * 2002-05-31 2005-10-20 プロテオテック・インコーポレイテッド アミロイド疾患およびシヌクレイノパチー（例えばアルツハイマー病、タイプ２型糖尿病、およびパーキンソン病）を処置するための化合物、組成物、および方法
WO2006094237A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators
JP2008536941A (ja) * 2005-04-20 2008-09-11 ゼノン・ファーマシューティカルズ・インコーポレイテッド オキシインドール化合物および治療剤としてのその使用
WO2008090382A1 (en) * 2007-01-25 2008-07-31 The University Of Sheffield Thiazole and oxazole derivatives for use in the treatment of prion diseases, cancer and conditions of the central nervous system as well as in the regulation of stem cells
WO2008156869A2 (en) * 2007-06-20 2008-12-24 Sirtris Pharmaceuticals, Inc. Sirtuin modulating thiazolopyridine compounds
WO2009055828A1 (en) * 2007-10-25 2009-04-30 Medivation Technologies, Inc. New tetracyclic compounds
WO2009064388A2 (en) * 2007-11-09 2009-05-22 Liu Jun O Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
ALAN R. KATRITZKY, ET AL.: "Convenient Synthesis of Novel N-Substituted-5-aminothiazole Derivatives", JOURNAL OF ORGANIC CHEMISTRY, vol. 65(23), JPN6016007801, 2000, pages 8077 - 8079, ISSN: 0003268325 *
CLAUDIO GIORDANO: "Formation of a thiazole ring in the α-thioamidoalkylation of acetylenes", GAZZETTA CHIMICA ITALIANA, vol. 105(11-12), JPN6016007799, 1975, pages 1265 - 71, ISSN: 0003268324 *
DIAS N: "DRUGS TARGETING MITOCHONDRIAL FUNCTIONS TO CONTROL TUMOR CELL GROWTH", BIOCHEMICAL PHARMACOLOGY, vol. V70 N1, JPN5013005130, 1 July 2005 (2005-07-01), GB, pages 1 - 12, ISSN: 0003040921 *
HIROSHI YAMANAKA, ET AL.: "On the reactivity of halo-1,3-azoles and related compounds toward aromatic SN2 substitution", HETEROCYCLES, vol. 31(6), JPN6016007798, 1990, pages 1115 - 27, ISSN: 0003268323 *
HOYE ADAM T: "TARGETING MITOCHONDRIA", ACCOUNTS OF CHEMICAL RESEARCH, vol. V41 N1, JPN5013005129, January 2008 (2008-01-01), pages 87 - 97, ISSN: 0003040920 *
METWALLY, SAOUD A. M.; YOUNES, MANSOUR I.; ABBAS, HESSIN H.: "Some reactions of N-ethylisatin with methyl ketones", ACTA CHIMICA HUNGARICA, vol. 126(5), JPN6015012183, 1989, pages 591 - 7, ISSN: 0003040916 *
POPP F D: "POTENTIAL ANTICONVULSANTS 5.THE CONDENSATION OF ISATINS WITH C-ACETYL HETEROCYCLIC COMPOUNDS", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. V19 N3, JPN5013005131, 1982, pages 589 - 592, ISSN: 0003040915 *
REGISTRY（STN）[ONLINE], JPN7015000814, ISSN: 0003040907 *
REGISTRY（STN）[ONLINE], JPN7015000815, ISSN: 0003040908 *
REGISTRY（STN）[ONLINE], JPN7015000816, ISSN: 0003040909 *
REGISTRY（STN）[ONLINE], JPN7015000817, ISSN: 0003040910 *
REGISTRY（STN）[ONLINE], JPN7015000819, ISSN: 0003040911 *
REGISTRY（STN）[ONLINE], JPN7015000821, ISSN: 0003040912 *
REGISTRY（STN）[ONLINE], JPN7015000822, ISSN: 0003040913 *
REGISTRY（STN）[ONLINE], JPN7015000823, ISSN: 0003040914 *
REGISTRY（STN）[ONLINE], JPN7016000480, ISSN: 0003268326 *
REGISTRY（STN）[ONLINE], JPN7016000481, ISSN: 0003268327 *
REGISTRY（STN）[ONLINE], JPN7016000482, ISSN: 0003268328 *
REGISTRY（STN）[ONLINE], JPN7016000483, ISSN: 0003268329 *
REGISTRY（STN）[ONLINE], JPN7016000484, ISSN: 0003268330 *
REGISTRY（STN）[ONLINE], JPN7016000485, ISSN: 0003268331 *
SUZUKI: "PHOTOCHEMISTRY OF 2,3-BENZO-2,4-CYCLOOCTADIENONES", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. V99 N15, JPN5013005132, 20 July 1977 (1977-07-20), pages 5083 - 5090, ISSN: 0003040917 *
SZEWCZYK ADAM: "MITOCHONDRIA AS A PHARMACOLOGICAL TARGET", PHARMACOLOGICAL REVIEWS, vol. V54 N1, JPN5013005128, March 2002 (2002-03-01), pages 101 - 127, ISSN: 0003040919 *
YAKIMOVICH S I: "TAUTOMERISM OF [BETA]-KETOESTER ACYLHYDRAZONES", RUSSIAN JOURNAL OF GENERAL CHEMISTRY, vol. V64 N9, JPN5013005133, 1994, pages 1339 - 1344, ISSN: 0003040918 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020019786A (ja) * 2015-04-30 2020-02-06 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント オキシンドール化合物およびその医薬組成物
JP2021059578A (ja) * 2015-04-30 2021-04-15 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント オキシンドール化合物およびその医薬組成物
JP7091437B2 (ja) 2015-04-30 2022-06-27 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント オキシンドール化合物およびその医薬組成物

Also Published As

Publication number Publication date
CA2794018C (en) 2016-05-10
AU2011232347A1 (en) 2012-10-04
EP2550260A1 (en) 2013-01-30
AU2011232347B2 (en) 2015-08-06
JP2016188257A (ja) 2016-11-04
WO2011119869A1 (en) 2011-09-29
US20130137728A1 (en) 2013-05-30
JP2015232051A (ja) 2015-12-24
CA2794018A1 (en) 2011-09-29
US20160237074A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
JP2016188257A (ja) 変性疾患を治療するための組成物および方法
US10588898B2 (en) Opioid receptor ligands and methods of using and making same
JP5313125B2 (ja) スルホンアミド誘導体
JP6556154B2 (ja) イソキノリン誘導体及びその使用
RU2376300C1 (ru) Сульфонамидное соединение
ES2581386T3 (es) Activadores de la glucoquinasa
US20080255222A1 (en) Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
CA3008637A1 (en) Combinations of opioid receptor ligands and cytochrome p450 inhibitors
KR101732989B1 (ko) 1형 11-베타-하이드록시스테로이드 데하이드로게나제의 저해 화합물
CN104411311A (zh) 取代的苯甲酰胺及其用途
CN102724975A (zh) IRE-1α抑制剂
JP2004510772A (ja) タンパク質Ｊｕｎ−キナーゼのインヒビターとしての医薬的活性親水性スルホンアミド誘導体
EP1802572B1 (de) Indol derivative als inhibitoren der löslichen adenylatzyklase
AU2015204390A1 (en) Compositions and methods for the treatment of degenerative diseases
EP2036906A1 (de) Azaindole als Inhibitoren der löslichen Adenylatzyklase
CA3096146C (en) Bumetanide derivatives for the therapy of hyperhidrosis
DE102005027274A1 (de) Inhibitoren der löslichen Adenylatzyklase
KR20010092424A (ko) 신규 형태의 축합 피리다지논 화합물
CN121045075A (zh) 一类5,7-二氯-1,2,3,4-四氢异喹啉衍生物及其制备方法与应用
BR112019017514A2 (pt) Composto, mistura, métodos para tratar uma tauopatias e para inibir uma glicosidase, e, composição farmacêutica
BR112017004868B1 (pt) Derivados de pirrolopirimidina como antagonistas do receptor nmda nr2b e composição farmacêutica que os compreende
NZ713143B2 (en) Opioid receptor ligands and methods of using and making same
HK1191179B (en) Opioid receptor ligands and methods of using and making same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160630